Wolff Wiese Magana LLC Buys 3,042 Shares of Novo Nordisk A/S (NYSE:NVO)

Wolff Wiese Magana LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 25,350.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,054 shares of the company’s stock after acquiring an additional 3,042 shares during the quarter. Wolff Wiese Magana LLC’s holdings in Novo Nordisk A/S were worth $263,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Brown Brothers Harriman & Co. raised its stake in shares of Novo Nordisk A/S by 52.3% in the second quarter. Brown Brothers Harriman & Co. now owns 35,679 shares of the company’s stock valued at $5,093,000 after purchasing an additional 12,257 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Novo Nordisk A/S by 2.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 77,494 shares of the company’s stock worth $11,061,000 after buying an additional 1,860 shares in the last quarter. Citizens Financial Group Inc. RI lifted its position in shares of Novo Nordisk A/S by 1.0% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 14,038 shares of the company’s stock worth $2,004,000 after buying an additional 134 shares during the period. Pekin Hardy Strauss Inc. boosted its stake in Novo Nordisk A/S by 20.1% in the 2nd quarter. Pekin Hardy Strauss Inc. now owns 7,165 shares of the company’s stock valued at $1,023,000 after buying an additional 1,200 shares in the last quarter. Finally, Alpha Financial Partners LLC grew its position in Novo Nordisk A/S by 8.1% in the second quarter. Alpha Financial Partners LLC now owns 1,739 shares of the company’s stock valued at $248,000 after acquiring an additional 130 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $83.12 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $80.05 and a twelve month high of $148.15. The business’s 50 day moving average price is $99.26 and its two-hundred day moving average price is $118.18. The company has a market cap of $373.00 billion, a PE ratio of 26.90, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NVO. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.